Evidence map›Paper›PMID 35608749›Full record

ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2022

Dengue Vaccines: An Update.

Jesús M Torres-Flores, Arturo Reyes-Sandoval, Ma Isabel Salazar

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
24.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jesús M Torres-FloresConsejo Nacional de Ciencia y Tecnología, 03940, Mexico, DF, Mexico.
Arturo Reyes-SandovalInstituto Politécnico Nacional, 11340, Mexico, DF, Mexico.
Ma Isabel SalazarInstituto Politécnico Nacional, 11340, Mexico, DF, Mexico. isalazarsan@yahoo.com.ORCID http://orcid.org/0000-0003-2490-8462
Instituto Politécnico Nacional · MXSecretaría de Ciencia, Humanidades, Tecnología e Innovación · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue is one of the most prevalent mosquito-borne diseases in the world, affecting an estimated 390 million people each year, according to models. For the last two decades, efforts to develop safe and effective vaccines to prevent dengue virus (DENV) infections have faced several challenges, mostly related to the complexity of conducting long-term studies to evaluate vaccine efficacy and safety to rule out the risk of vaccine-induced DHS/DSS, particularly in children. At least seven DENV vaccines have undergone different phases of clinical trials; however, only three of them (Dengvaxia

Indexed as

DengueDengue VaccinesAnimalsAntibodies, ViralChildHumansAntibodies, ViralDengue Vaccines

Identifiers

PMID35608749
PMCPMC9127483
OpenAlexW4281401569

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.